CD20 is a transmembrane phosphoprotein located on the surface of B lymphocytes, mainly expressed in the pre-B cell to mature B cell stage. Anti-CD20 mAb exerts efficacy in killing B cell-derived tumors by antibody-dependent cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and inhibition of cell growth (direct inhibition) by binding to CD20 molecules.
Anti-CD20 monoclonal antibody has undergone a series of optimizations and improvements since its inception. The first generation is a human-mouse chimeric monoclonal antibody represented by rituximab; the second generation is a human-derived monoclonal antibody represented by olafitozumab (trade name: Arzerra), which reduces heterogeneity. The third generation is an Fc-segmented monoclonal antibody represented by alteizumab (trade name Gazyva), which enhances the ADCC/ADCP effect and weakens the CDC effect.
Rituximab entered China in 2000 and has been approved for the treatment of three types of non-Hodgkin’s lymphoma. There are currently 54 monoclonal antibody against CD20 in the world, including 16 models, 2 for application, 10 for phase III, 2 for phase II, 14 for phase I, 6 for clinical, and 4 for preclinical.
Anti-CD20 monoclonal antibody global research and development
Note: Both are the highest in the world. Bispecific antibodies, single chain antibodies, cell therapy, and gene therapy directed against the CD20 target are not included.